Seminars in Nuclear Medicine
Volume 31, Issue 3 , Pages 238-250 , July 2001

Nuclear endocrinology as a monitoring tool

  • Yodphat Krausz

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Yodphat Krausz, MD, Department of Nuclear Medicine, Hadassah University Hospital, PO Box 12000, Jerusalem, 91120 Israel.

References 

  1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306
  2. Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: Including comments on the role of serum thyroglobulin monitoring in tumor surveillance. In: Semin Nucl Med. 30:2000;p. 107–114
  3. Lubin E, Mechlis-Frish S, Zatz S, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med. 1994;35:257–262
  4. Bocher M, Balan A, Krausz Y, et al. Gamma camera-mounted anatomical x-ray tomography: Technology, system characteristics and first images. Eur J Nucl Med. 2000;27:619–627
  5. Cavalieri RR. Nuclear imaging in the management of thyroid carcinoma. Thyroid. 1996;6:485–492
  6. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II Study). J Clin Endocrinol Metab. 1994;78:188–196
  7. Ladenson PW, Braverman LE, Mazzaferri E, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997;337:888–896
  8. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877–3885
  9. Ladenson PW. Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. In: Semin Nucl Med. 30:2000;p. 98–106
  10. Venkataraman GM, Yatin M, Ain KB. Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell line, KAT-50. Thyroid. 1998;8:63–69
  11. Shapiro B, Rufini V, Jarwan A, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. In: Semin Nucl Med. 30:2000;p. 115–132
  12. Harder W, Lind P, Molnar M, et al. Thallium-201 uptake with negative iodine-131 scintigraphy and serum thyroglobulin in metastatic oxyphilic papillary thyroid carcinoma. J Nucl Med. 1998;39:236–238
  13. Grünwald F, Menzel C, Bender H, et al. Comparison of 18-FDG-PET with 131-iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid. 1997;7:327–335
  14. Baudin E, Schlumberger M, Lumbroso J, et al. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: Contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab. 1996;81:2541–2544
  15. Chung JK, So Y, Lee JS, et al. Value of FDG-PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med. 1999;40:986–992
  16. Balon HR, Fink-Bennett D, Stoffer SS. Technetium-99m-sestamibi uptake by recurrent Hürthle cell carcinoma of the thyroid. J Nucl Med. 1992;33:1393–1395
  17. Feine U, Leitzenmayer R, Hanke JP, et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468–1472
  18. Jeevanram RK, Shah DH, Sharma SM, et al. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol. 1986;13:277–279
  19. Anteby I, Pe'er J, Uziely B, et al. Thyroid carcinoma metastasis to the choroid responding to systemic I-131 therapy. Am J Ophthalmol. 1992;113:461–462
  20. Schlumberger M, Mancusi F, Baudin E, et al. 131I therapy for elevated thyroglobulin levels. Thyroid. 1997;7:273–276
  21. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994;78:629–634
  22. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-A quantitative radiation dosimetric approach: Outcome and validation in 85 patients. J Nucl Med. 1992;33:1132–1136
  23. Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med. 1999;43:313–323
  24. Buhr HJ, Kallinowski F, Raue F, et al. Microsurgical neck dissection for occulty metastasizing medullary thyroid carcinoma. Three-year results. Cancer. 1993;72:3685–3693
  25. Tisell LE, Hansson G, Jansson S, et al. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986;99:60–66
  26. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–1148
  27. Dörr U, Sautter-Bihl ML, Bihl H. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid. In: Semin Oncol. 21:1994;p. 42–45suppl 13
  28. (suppl) Dörr U, Würstlin S, Frank-Raue K, et al. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: A comparative study. Horm Metab Res. 1993;27:48–55
  29. Frank-Raue K, Raue F, Buhr HJ, et al. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: High sensitivity of selective venous catheterization. Thyroid. 1992;2:113–117
  30. Arnstein NB, Juni JE, Sisson JC, et al. Recurrent medullary carcinoma of the thyroid demonstrated by thallium-201 scintigraphy. J Nucl Med. 1986;27:1564–1568
  31. Udelsman R, Ball D, Baylin SB, et al. Preoperative localization of occult medullary carcinoma of the thyroid gland with single-photon emission tomography dimercaptosuccinic acid. Surgery. 1993;114:1083–1089
  32. [letter to the editor] Endo K, Shiomi K, Kasagi K, et al. Imaging of medullary thyroid carcinoma with 131I-MIBG. Lancet. 1984;2(8396):233
  33. 18 Lebouthillier G, Morais J, Picard M, et al. Tc-99m sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid. Clin Nucl Med. 1993;657–661
  34. Manil L, Boudet F, Motte P, et al. Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma. Cancer Res. 1989;49:5480–5485
  35. Vuillez JPH, Peltier P, Caravel JP, et al. Immunoscintigraphy using 111In-labeled F(ab')2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrinol Metab. 1992;74:157–163
  36. Reubi JC, Krenning E, Lamberts SWJ, et al. In vitro detection of somatostatin receptors in human tumors. Metabolism. 1992;41(suppl 2):104–110
  37. Adams S, Baum RP, Hertel A, et al. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med. 1998;25:1277–1283
  38. Limouris GS, Giannakopoulos V, Stavraka A, et al. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 MIBG scint imaging in neural crest tumors. Anticancer Res. 1997;17:1589–1592
  39. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76:1413–1417
  40. Krausz Y, Ish-Shalom S, De Jong RBJ, et al. Somatostatin-receptor imaging of medullary thyroid carcinoma. Clin Nucl Med. 1994;19:416–421
  41. Krausz Y, Rosler A, Guttmann H, et al. Somatostatin receptor scintigraphy for early detection of regional and distant metastasis of medullary carcinoma of the thyroid. Clin Nucl Med. 1999;24:256–260
  42. Behr TM, Behe M, Becker W. Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med. 1999;43:268–280
  43. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its malogs in the diagnosis and treatment of tumors. Endocr Rev. 1991;12:450–482
  44. Roos BA, Lindall AW, Ells J, et al. Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer. J Clin Endocrinol Metabol. 1981;52:187–194
  45. Reubi JC, Chayvialle JA, Frane B, et al. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991;64:567–573
  46. (suppl) Behr TM, Gratz S, Markus PM, et al. Anticarcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: Are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?. Cancer. 1997;80:2436–2457
  47. Musholt TJ, Musholt PB, Dehdashti F, et al. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: A clinical and molecular study. Surgery. 1997;122:1049–1060
  48. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996;67:644–647
  49. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998;25:424–430
  50. Maurea S, Cuocolo A, Reynolds JC, et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: Comparison with CT and MRI. J Nucl Med. 1993;34:173–179
  51. Freitas JE. Adrenal cortical and medullary imaging. In: Semin Nucl Med. 25:1995;p. 235–250
  52. Home T, Glaser B, Krausz Y, et al. Unusual causes of I-13 metaiodobenzylguanidine uptake in non-neural crest tissue. Clin Nucl Med. 1991;16:239–242
  53. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39:679–688
  54. Krempf M, Lumbroso J, Mornex R, et al. Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 1991;72:455–461
  55. Tenenbaum F, Lumbroso J, Schlumberger M, et al. Comparison of radiolabeled octreotide and metaiodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med. 1995;36:1–6
  56. Shulkin BL, Thompson NW, Shapiro B, et al. Pheochromocytomas: Imaging with 2-[fluorine-18] fluoro-2-deoxy-D-glucose PET. Radiology. 1999;212:35–41
  57. Shulkin BL, Wieland DM, Schwaiger M, et al. PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J Nucl Med. 1992;33:1125–1131
  58. Ott RJ, Tait D, Flower MA, et al. Treatment planning for 1311-MIBG radiotherapy of neural crest tumours using 124I-MIBG positron emission tomography. Br J Radiol. 1992;65:787–791
  59. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med. 1999;43:217–223
  60. Leung A, Shapiro B, Hattner R, et al. Specificity of radoiodinated MIBG for neural crest tumors in childhood. J Nucl Med. 1997;38:1352–1357
  61. Heij HA, Rutgers EJ, de Kraker J, et al. Intraoperative search for neuroblastoma by MIBG and radioguided surgery with the gamma detector. Med Pediatr Oncol. 1997;28:171–174
  62. Rufini V, Fisher GA, Shulkin BL, et al. Iodine-123-MIBG imaging of neuroblastoma: Utility of SPECT and delayed imaging. J Nucl Med. 1996;37:1464–1468
  63. Shulkin BL, Shapiro B, Hutchinson RJ. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma. J Nucl Med. 1992;33:1735–1740
  64. Hoefnagel CA. Nuclear medicine therapy of neuroblastoma. Q J Nucl Med. 1999;43:336–343
  65. Matthay KK, DeSantes K, Hasegawa B, et al. Phase I dose escalation of 13II-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998;16:229–236
  66. Shalaby-Rana E, Majd M, Andrich MP, et al. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification and patient outcome. Clin Nucl Med. 1997;22:315–319
  67. Shulkin BL, Hutchinson RJ, Castle VP, et al. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:743–750
  68. Francis IR, Gross MD, Shapiro B, et al. Integrated imaging of adrenal disease. Radiology. 1992;184:1–13
  69. Dunnick NR, Korobkin M, Francis I. Adrenal radiology: Distinguishing benign from malignant adrenal masses. AJR Am J Roentgenol. 1996;167:861–867
  70. Evans HL, Vassilopoulou-Sellin R. Adrenal cortical neoplasms. A study of 56 cases. Am J Clin Pathol. 1996;105:76–86
  71. Bergström M, Bonasera TA, Lu L, et al. In vitro and in vivo primate evaluation of carbon-11-metomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med. 1998;39:982–989
  72. Bergström M, Juhlin C, Bonasera TA, et al. PET imaging of adrenal cortical tumors with the 11β-hydroxylase tracer 11C-metomidate. J Nucl Med. 2000;41:275–282
  73. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;194:131–134
  74. Harrison J, Ali A, Bonomi P, et al. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy. Amer Surg. 2000;66:432–436
  75. Kreissig R, Amthauer H, Krude H, et al. The use of FDG-PET and CT for the staging of adrenocortical carcinoma in children. Pediatr Radio. 2000;30:306
  76. (abstr) Becherer A, Vierhapper H, Poetzi C, et al. FDG-PET in adrenocortical carcinoma. Eur J Nucl Med. 2000;27:903
  77. Lamberts SWJ, Chayvialle JA, Krenning EP. The visualization of gastroenteropancreatic endocrine tumors. Metabolism. 1992;41(suppl 2):111–115
  78. Reubi JC, Kvols L, Krenning E, et al. In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncol. 1991;30:463–468
  79. Reubi JC, Laissue J, Waser B, et al. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann NY Acad Sci. 1994;733:122–137
  80. Krenning EP, Kwekkeboom DJ, Reubi JC, et al. In 111-octreotide scintigraphy in oncology. Metabolism. 1992;41(suppl 2):83–86
  81. Adams S, Baum RP, Hertel A, et al. Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med. 1998;39:1155–1160
  82. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  83. (suppl) Joseph K, Stapp J, Reinecke J, et al. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors. Horm Metab Res. 1993;27:28–35
  84. Kwekkeboom DJ, Krenning EP, Bakker WH, et al. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med. 1993;20:283–292
  85. Shi W, Johnston CF, Buchanan KD, et al. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): A comparative study with CT and MR imaging. QJM. 1998;91:295–301
  86. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann NY Acad Sci. 1994;733:416–424
  87. Krausz Y, Pfeffer MR, Glaser B, et al. Somatostatinreceptor scintigraphy of subcutaneous and thyroid metastases from bronchial carcinoid. J Nucl Med. 1996;37:1537–1539
  88. Jamar F, Fiasse R, Leners N, et al. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: Safety, efficacy and impact on patient management. J Nucl Med. 1995;36:542–549
  89. Krausz Y, Bar-Ziv J, de Jong RBJ, et al. Somatostatinreceptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol. 1998;93:66–70
  90. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50:5969–6977
  91. (suppl) Trautmann ME, Neuhaus Ch, Lenze H, et al. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors. Horm Metab Res. 1993;27:24–27
  92. Kvols LK. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann NY Acad Sci. 1994;733:464–470
  93. Arnold R, Neuhaus C, Benning R, et al. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg. 1993;17:511–519
  94. [letter to editor] Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417–418
  95. De Jong M, Breeman WA, Bernard HF, et al. Therapy of neuroendocrine tumors with radiolabeled somatostatinanalogues. Q J Nucl Med. 1999;43:356–366

PII: S0001-2998(01)80023-4

doi: 10.1053/snuc.2001.23530

Seminars in Nuclear Medicine
Volume 31, Issue 3 , Pages 238-250 , July 2001

Article Tools